WCG
BLRX

Weaver Consulting Group’s BioLineRX BLRX Stock Holding History

Weaver Consulting Group’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-275
Closed -$2.35K – 224
2024
Q4 		$2.35K Sell
275
-469
-63% -$6.92K ﹤0.01% 220
2024
Q3 		$15.9K Buy
744
+321
+76% +$8.82K 0.01% 223
2024
Q2 		$9.64K Buy
+423
New +$11.4K ﹤0.01% 204

Other funds holding BLRX

Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Weaver Consulting Group's BLRX Position: Q1 2025 in Review

Weaver Consulting Group sold out of BioLineRX (BLRX) in Q1 2025, closing a stake of 275 shares — an estimated $2.35K sold.

Weaver Consulting Group first reported a position in BLRX in Q2 2024 and held it in 3 quarters. The position peaked at $15.9K in Q3 2024. 12 funds tracked by Wall St. Rank hold BLRX as of Q1 2025.

  • Weaver Consulting Group reported no remaining BioLineRX position as of Q1 2025 after selling out during the quarter.
  • Weaver Consulting Group sold 275 BioLineRX shares in Q1 2025, an estimated $2.35K.
  • Weaver Consulting Group first reported a position in BioLineRX in Q2 2024 and held it in 3 quarters.
  • Weaver Consulting Group's BioLineRX position peaked at $15.9K in Q3 2024.
  • 12 funds tracked by Wall St. Rank held BioLineRX as of Q1 2025.

Based on Weaver Consulting Group's 13F filing for Q1 2025, filed 28 Apr 2025.